The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.
Panel Offers Consensus Recommendations for MRD Assessment in CLL
November 24th 2021The recommendations come at a time when treatments for chronic lymphocytic leukemia (CLL), such as venetoclax, are making deep remissions and undetectable minimal residual disease (MRD) after a fixed duration of treatment feasible goals.
Read More
New Research Underscores Need for More Diversity in Precision Oncology Studies
November 11th 2021Across all studies included, observed-to-expected ratios showed that White and Asian patients were overrepresented while Black patients, Hispanic patients, and American Indian/Alaskan Native patients were underrepresented.
Read More
Researchers Hope Single-Cell Tumor Immune Atlas Can Improve Predictions in Precision Oncology
October 26th 2021A pan-cancer reference atlas provides a framework for an immune-based patient stratification that study authors expect to be predictive for patient prognosis and immunotherapy response at an elevated level after further studies.
Read More
Providing Patients With Cancer Access to Affordable Housing During Treatment
October 7th 2021Patients traveling for cancer treatment often incur financial burdens. The members of the Alliance of Dedicated Cancer Centers should play a role in mitigating housing-associated costs for patients during cancer treatment.
Read More
MRD Monitoring Useful Across Risk Groups in ALL
September 23rd 2021In a recent paper, researchers outlined the utility of minimal residual disease (MRD) among patient with acute lymphoblastic leukemia (ALL) and how its monitoring at specific timepoints has proven useful for stratifying patients and helping to ensure appropriate treatment decisionsMRD
Read More
Researchers Outline Ongoing Potential of ctDNA Analysis in GEA
September 19th 2021Unlike the success seen in other cancer types, biomarker-driven treatment advances in gastroesophageal adenocarcinoma (GEA) have been hindered by its genomic heterogeneity. A significant proportion of patients also develop resistant subclones through selective pressure, resulting in disease progression.
Read More
Phase 3 Data Solidify Cemiplimab’s Role in Second-Line Treatment of Cervical Cancer
September 18th 2021In May, results showed that cemiplimab (Libtayo, Regeneron/Sanofi) produced significant benefits: a 31% reduction in the risk of death and a 25% reduction in the risk of disease progression.
Read More
Describing Sensitivity of ddPCR in Philadelphia-Positive ALL
September 2nd 2021The study, using a BCR/ABL1 assay, found that the novel method is able to detect minimal residual disease (MRD) in a larger range of patients compared with quantitative real‐time polymerase chain reaction, the method currently used to detect MRD.
Read More
Study Finds Contrasting Genomic Profiles Among Tissue Samples, Liquid Biopsies of Prostate Cancer
August 25th 2021The genomic alterations in prostate cancer were detected from tissue biopsies of primary tumors and metastatic sites as well as from liquid biopsies of circulating tumor DNA, the latter of which has emerged as an increasingly popular method for genomic analyses across various types of cancer.
Read More
Precision Oncology Briefs: Cutting Breast Cancer Deaths; Enfortumab Vedotin; Rare CRC Mutations
August 14th 2021A meta-analysis showed adding trastuzumab to chemotherapy for the treatment of early-stage, HER2-positive breast cancer could cut deaths worldwide; a researcher discusses the promise of enfortumab vedotin for advanced urothelial cancers; more research is needed in rare genomic alterations in subsets of colorectal cancer (CRC).
Read More